Leadership changes, September 2026
Executive appointments and departures from SEC 8-K filings, updated within hours of each filing.
Updated Nov 6, 2026
Changes
1,052
Appointments
619
Departures
64
Browse by role
September 2026
Get new CFO appointments the day the filing lands.
Filters
1,052 changes
| Filing date | Company | Person | Role | Change | Effective date | Source |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | First Carolina Financial Services, Inc. | Steven G. Deaton | Chief Financial Officer and Chief Risk OfficerCFO | Departed | Jan 1, 2027 | SEC 8-K |
| Sep 18, 2026 | Genpact LTD | Michael Weiner | Chief Financial OfficerCFO | Departed | Sep 8, 2026 | SEC 8-K |
| Sep 18, 2026 | Glucotrack, Inc. | Paul V. Goode | DirectorDirector | Departed | Sep 14, 2026 | SEC 8-K |
| Sep 18, 2026 | Gold.com, Inc. | Cary Dickson | Executive Vice President and Chief Financial OfficerCFO | Departed | Sep 18, 2026 | SEC 8-K |
| Sep 18, 2026 | Gold.com, Inc. | Jill Van | Chief Financial OfficerCFO | Appointed | Sep 18, 2026 | SEC 8-K |
| Sep 18, 2026 | HEALTHY EXTRACTS INC. | Bill Croyle | DirectorDirector | Departed | Sep 13, 2026 | SEC 8-K |
| Sep 18, 2026 | Inhibitor Therapeutics, Inc. | Francis E. O’Donnell | DirectorDirector | Appointed | Sep 15, 2026 | SEC 8-K |
| Sep 18, 2026 | Inhibitor Therapeutics, Inc. | Samuel J. Sears | DirectorDirector | Appointed | Sep 15, 2026 | SEC 8-K |
| Sep 18, 2026 | Inhibitor Therapeutics, Inc. | Niraj Vasisht | DirectorDirector | Appointed | Sep 15, 2026 | SEC 8-K |
| Sep 18, 2026 | Inhibitor Therapeutics, Inc. | Michelle Yanez | DirectorDirector | Appointed | Sep 15, 2026 | SEC 8-K |
| Sep 18, 2026 | Inhibitor Therapeutics, Inc. | Michael Jerman | DirectorDirector | Appointed | Sep 15, 2026 | SEC 8-K |
| Sep 18, 2026 | Inhibitor Therapeutics, Inc. | Ronald E. Osman | DirectorDirector | Appointed | Sep 15, 2026 | SEC 8-K |
| Sep 18, 2026 | INTELLINETICS, INC. | Matthew Chretien | Chief Strategy OfficerChief Strategy Officer | Departed | Sep 1, 2026 | SEC 8-K |
| Sep 18, 2026 | INVE Technologies, Inc. | Kirsten Newquist | Chief Executive OfficerCEO | Departed | Sep 21, 2026 | SEC 8-K |
| Sep 18, 2026 | INVE Technologies, Inc. | James Greenwell | Interim Chief Executive OfficerCEO | Appointed | Sep 21, 2026 | SEC 8-K |
| Sep 18, 2026 | Okta, Inc. | Emilie Choi | Class I director of the Board of DirectorsClass I director of the Board of Directors | Departed | Sep 14, 2026 | SEC 8-K |
| Sep 18, 2026 | Okta, Inc. | Helen Riley | independent director of the Companyindependent director of the Company | Appointed | Sep 18, 2026 | SEC 8-K |
| Sep 18, 2026 | PENTAIR plc | Louis V. Pinkham | director of the Company and a member of the Audit and Finance Committee of the Boarddirector of the Company and a member of the Audit and Finance Committee of the Board | Appointed | Sep 17, 2026 | SEC 8-K |
| Sep 18, 2026 | Q/C TECHNOLOGIES, INC. | Yossef Ehrlichman | Chief Technology OfficerCTO | Appointed | Sep 14, 2026 | SEC 8-K |
| Sep 18, 2026 | SARATOGA INVESTMENT CORP. | Henri J. Steenkamp | Chief Financial Officer, Chief Compliance Officer, Treasurer and SecretaryCFO | Departed | Oct 31, 2026 | SEC 8-K |
Steven G. Deaton CFO
Filed Sep 18, 2026Effective Jan 1, 2027SEC 8-K
- Genpact LTDDeparted
Michael Weiner CFO
Filed Sep 18, 2026Effective Sep 8, 2026SEC 8-K
- Glucotrack, Inc.Departed
Paul V. Goode Director
Filed Sep 18, 2026Effective Sep 14, 2026SEC 8-K
- Gold.com, Inc.Departed
Cary Dickson CFO
Filed Sep 18, 2026Effective Sep 18, 2026SEC 8-K
- Gold.com, Inc.Appointed
Jill Van CFO
Filed Sep 18, 2026Effective Sep 18, 2026SEC 8-K
- HEALTHY EXTRACTS INC.Departed
Bill Croyle Director
Filed Sep 18, 2026Effective Sep 13, 2026SEC 8-K
- Inhibitor Therapeutics, Inc.Appointed
Francis E. O’Donnell Director
Filed Sep 18, 2026Effective Sep 15, 2026SEC 8-K
- Inhibitor Therapeutics, Inc.Appointed
Samuel J. Sears Director
Filed Sep 18, 2026Effective Sep 15, 2026SEC 8-K
- Inhibitor Therapeutics, Inc.Appointed
Niraj Vasisht Director
Filed Sep 18, 2026Effective Sep 15, 2026SEC 8-K
- Inhibitor Therapeutics, Inc.Appointed
Michelle Yanez Director
Filed Sep 18, 2026Effective Sep 15, 2026SEC 8-K
- Inhibitor Therapeutics, Inc.Appointed
Michael Jerman Director
Filed Sep 18, 2026Effective Sep 15, 2026SEC 8-K
- Inhibitor Therapeutics, Inc.Appointed
Ronald E. Osman Director
Filed Sep 18, 2026Effective Sep 15, 2026SEC 8-K
- INTELLINETICS, INC.Departed
Matthew Chretien Chief Strategy Officer
Filed Sep 18, 2026Effective Sep 1, 2026SEC 8-K
- INVE Technologies, Inc.Departed
Kirsten Newquist CEO
Filed Sep 18, 2026Effective Sep 21, 2026SEC 8-K
- INVE Technologies, Inc.Appointed
James Greenwell CEO
Filed Sep 18, 2026Effective Sep 21, 2026SEC 8-K
- Okta, Inc.Departed
Emilie Choi Class I director of the Board of Directors
Filed Sep 18, 2026Effective Sep 14, 2026SEC 8-K
- Okta, Inc.Appointed
Helen Riley independent director of the Company
Filed Sep 18, 2026Effective Sep 18, 2026SEC 8-K
- PENTAIR plcAppointed
Louis V. Pinkham director of the Company and a member of the Audit and Finance Committee of the Board
Filed Sep 18, 2026Effective Sep 17, 2026SEC 8-K
- Q/C TECHNOLOGIES, INC.Appointed
Yossef Ehrlichman CTO
Filed Sep 18, 2026Effective Sep 14, 2026SEC 8-K
- SARATOGA INVESTMENT CORP.Departed
Henri J. Steenkamp CFO
Filed Sep 18, 2026Effective Oct 31, 2026SEC 8-K